Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    13

Stocks News & Analysis

stocks

ASX healthcare share remains undervalued ahead of earnings

Margin recovery remains the key driver for this ASX healthcare share.
stocks

Alphabet earnings: Strong AI monetization continues to spearhead results

We maintain our fair value estimate for wide-moat Alphabet.
stocks

AMD: We’re pleased with Anthropic Partnership ahead of advancing AI event

We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,941.5032.70-0.36%
CAC 408,372.280.000.00%
DAX 4025,099.00335.881.36%
Dow JONES (US)51,947.25235.600.46%
FTSE 10010,736.2397.060.91%
HKSE24,963.23247.58-0.98%
NASDAQ24,975.82161.87-0.64%
Nikkei 22564,611.151,811.45-2.73%
NZX 50 Index13,772.2923.02-0.17%
S&P 5007,411.983.680.05%
S&P/ASX 2008,772.3023.40-0.27%
SSE Composite Index3,814.2062.58-1.61%

Market Movers